Oral mucositis induced by anticancer treatments: Physiopathology and treatments

Therapeutics and Clinical Risk Management

Volumn 2, Issue 2, 2006, Pages 159-168

  D'Hondt, Lionel ^a   Lonchay, Christophe ^a   André, Marc ^a   Canon, Jean Luc ^a  

^a Centre Hospitalier Notre Dame et Reine Fabiola   (Belgium)

Author keywords

Chemotherapy; Oral mucositis; Palifermin; Radiotherapy

Indexed keywords

AES 14; ALKYLATING AGENT; AMIFOSTINE; AMPHOTERICIN B; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZYDAMINE; CARBOPLATIN; CHLORHEXIDINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GLUTAMINE DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MELPHALAN; METHOTREXATE; NARCOTIC ANALGESIC AGENT; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PALIFERMIN; PLACEBO; POLYMYXIN B; REPIFERMIN; TAXANE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC REACTION; CASE MANAGEMENT; CLINICAL TRIAL; COLON CANCER; COST BENEFIT ANALYSIS; CRYOTHERAPY; DRUG COST; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EDEMA; ERYTHEMA; FLUSHING; HUMAN; HYPESTHESIA; HYPOCALCEMIA; HYPOTENSION; LOW LEVEL LASER THERAPY; MOUTH DISCOMFORT; MOUTH DISEASE; MOUTH HYGIENE; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; PALLIATIVE THERAPY; PARESTHESIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; RADIATION INJURY; REVIEW; RISK FACTOR; SNEEZING; SOMNOLENCE; TASTE DISORDER; TONGUE DISEASE; TOOTH DISEASE; VOMITING;

EID: 33745439040     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.2.159     Document Type: Review

References (83)

1. Anderson PM, Schroeder G, Skubitz KM. 1998. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer, 83:1433-9.
2. Anderson PM, Ramsay NK, Shu XO, et al. 1998. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant, 22:339-44.
3. Andriea-Abadic N, Levade T. 2002. Sphingomyelin hydrolysis during apoptosis. Biochem Biophys Acta, 1585:126-34.
4. auf dem Keller U, Krampert M, Kümin A, et al. 2004 Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Biol, 83:607-12.
5. Balducci L, Exterrman M. 2000. Management of cancer in the older person: a practical approach. Oncologist, 20:224-37.
6. Barasch A, Peterson DE, Tanzer JM, et al. 1995. Heliun-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer, 76:2550-6.
7. Bardet E, Martin L, Calais G, et al. 2002. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Sem Oncol, 29(suppl 19):57-60.
8. Bellm LA, Epstein JB, Rose-Ped A, et al. 2000. Patients reports of complications of bone marrow transplantation. Support Care Cancer, 8:33-9.
9. Blazar BR, Weisdorf DJ, DeFor TE, et al. 2005. Palifermin (A rHuKGF molecule) is safe and well tolerated in patients (Pts) with hematologic malignancies (HM) undergoing high-dose chemoradiotherapy (HD-CRT) followed by allogeneic hematopoietic stem cell transplant (HSCT) [abstract]. Biol Blood Marrow Transplant, 11(suppl 1):11.
10. Braun S, Hanselmann C, Gassman MG, et al. 2002. Nrf2 transcription factor: a novel target of keratinocyte growth factor action regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol, 22:5492-505.
11. Brizel DM, Wasserman TH, Henke M, et al. 2000. Phase III randomised trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol, 18:3339-45.
12. Cascinu S, Fedeli A, Fedeli SL, et al. 1994. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatatis. Eur J Cancer B Oral Oncol, 30B:234-6.
13. Chedid M, Rubin JS, Csaky KG, et al. 1994. Regulation of keratinocyte growth factor gene expression by interleukin 1. J Biol Chem, 269:10753-7.
14. Chi KH, Chen CH, Chan WK, et al. 1995. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositisin head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol, 13:2620-8.
15. Cowen D, Tardieu C, Schubert M, et al. 1997. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplan: results of a double blind randomised trial. Int J Radiot Oncol Biol Phys, 38:697-703.
16. Dazzi C, Cariello A, Giovanis P, et al. 2003. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind randomised, placebo-controlled study. Ann Oncol, 14:559-63.
17. Donnelly JP, Bellm LA, Epstein JB, et al. 2003. Antimicrobial therapy to prevent or treat mucositis. Lancet Infect Dis, 3:405-12.
18. Dood MJ, Miaskowski C, Shiba GH, et al. 1999. Risk factors for chemotherapy-induced oral mucositis: dental appliance, oral hygiene, previous oral lesions, and a history of smoking. Cancer Invest, 17:278-84.
19. Dörr W, Spekl K, Farell C. 2002. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys, 54:245-51.
20. Elting L, Peterson D, Sonis ST. 2004. Late-breaking information from the 2004 ASCO annual meeting. Oral Mucositis Newsletter, 1:1-12.
21. Epstein JB, Tsang AHF, Warkentin D, et al. 2002. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 94:39-44.
22. Farell CL, Bready JV, Rex KL, et al. 1998. Keratinocyte Growth Factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res, 58:933-9.
23. Finch PW, Rubin JS, Miki T, et al. 1989. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science, 245:752-5.
24. Foote RL, Loprinzi CL, Frank AR et al. 1994. Randomized trial of chlorhexidine mouthwash for alleviation of radiation induced-mucositis. J Clin Oncol, 12:2630-3.
25. Freytes CO, Ratanathorn V, Taylor C, et al. 2004. Phase I/II randomised clinical trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hemotopoietic stem cell transplantation. Clin Cancer Res, 10:8318-24.
26. Frieling JT, Mulder JA, Hendriks T, et al. 1997. Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria effects of antibiotic treatment. Antimicrob Agents Chemother, 41:1439-43.
27. Genot MT, Klastersky J. 2005. Low level laser for prevention and therapy of oral mucositis induced by chemotherapy and/or radiotherapy. Curr Opin Oncol, 17:236-40.
28. Graham GJ, Ramenghi U, O'Connor MP, et al. 1992. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol, 82:589-95.
29. Henry S, D'Hondt L, André M, et al. 2004. Saccharomyces Cerevisiae fumgemia in a head and neck cancer patient: a case report and review of the literature. Acta Clin Belg, 59:220-2.
30. Hille A, Rave-Frank M, Pradier O, et al. 2003. Effect of keratinocyte growth factor on the proliferatio, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol, 79:119-128.
31. Hsu YR, Nybo R, Sullivan JK, et al. 1999. Heparin is essential for a single keratinocyte growth factor molecule to bind and form a complex with two molecules of the extracellular domain of its receptor. Biochemistry, 38:2523-34.
32. Innocenti M, Moscatelli G, Lopez S. 2002. Efficacy of Gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage, 24:456-7.
33. Jebb SA, Osborne RJ, Maughan TS, et al. 1994. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer, 70:732-5.
34. Just N, Tillie-Leblond I, Guery BP, et al. 2003. Keratinocyte growth factor (KGF) decreases ICAM-1 and VCAM-1 cell expression on bronchial epithelial cells. Clin Exp Immunol, 132:61-9.
35. Kannan V, Bapsy PP, Anantha N et al. 1997. Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiot Oncol Biol Phys, 37:1005-10.
36. Karthaus M, Rosenthal C, Huebner G, et al. 1998. Effect of topical oral G-CSF on oral mucositis: a randomized placebo-controlled trial. Bone Marrow Transplant, 22:781-5.
37. Komaki R, Lee JS, Kaplan B et al. 2002. Randomised phase III study of chemoradiation with or without amifostine for patients with favourable performance status inoperable stage II and III non-small cell lung cancer: preliminary results. Semin Radiot Oncol, 12(suppl 1):46-9.
38. Kuenen BC, Levi M, Meijers JC, et al. 2003. Potential role of platelets in endothelial damage during treatment with gemcitabine and the angiogenesis inhibitor SU5416. J Clin Oncol, 21:2192-8.
39. Larson P, Miakowski C, MacPhail L, et al. 1998. The PRO-SELF mouth aware program: an effective approach for reducing chemotherapy-induced mucositis. Cancer Nurs, 21:263-8.
40. Lockhart PB, Brennan MT, Kent ML, et al. 2005. Randomized controlled trial of pilocarpine hydrochloride for the moderation of oral mucositis during autologous blood stem cell transplantation. Bone Marrow Transplant, 35:713-20.
41. Lorusso D, Ferrandina G, Greggi S, et al. 2003. Phase III multicenter randomised trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol, 14:1086-93.
42. MacDonald K, Hill G, 2002. Keratinocyte growth factor (KGF) in haematology and oncology. Curr Pharm Des, 8:395-403.
43. Mahood DJ, Dose AM, Loprinzi CL, et al. 1991. Inhibition of fluouracil-induced stomatatis by oral cryotherapy. J Clin Oncol, 9:449-52.
44. Makkonen TA, Minn H, Jekunen A, et al. 2000. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomised study. Int J Radiat Oncol Biol Phys, 46:525-34.
45. Mascarin M, Franchin G, Minatel E, et al. 1999. The effect of granulocyte colony-stimulating factor on oral mucositisin head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncol, 35:203-8.
46. McManus LM, Ostrom KK, Laer C, et al. 1993. Radiation-induced increased platelet-activating factor activity in mixed saliva. Lab Invest, 68:118-24.
47. [MAC] Meta-Analysis Group in Cancer. 1998. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol, 16:3537-41.
48. Meropol NJ, Somer RA, Gutheil J, et al. 2003. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol, 21:1452-8.
49. Neumann TK, Foote MA. 2003. The development of supportive-care agents for patients with cancer. Biotechn Ann Rev, 9:397-416.
50. Oelmann E, Haghu S, Kulimova E, et al. 2004. Influence of keratinocyte growth factor on clonal growth of epithelial cells, lymphoma and leukaemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol, 25:1001-12.
51. Okuno SH, Woodhouse CO, Loprinzi CL, et al. 1999. Phase III controlled evaluation of glutamine for decreasing stomatatis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol, 22:258-61.
52. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. 2000. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood, 96:4350-6.
53. Panoskaltsis-Mortari A, Ingbar DH, Jung P, et al. 2000. KGF pretreatment decreases B7 and granzyme B expression and hastens repair in lungs of mice after allogeneic BMT. Am J Physiol Lung Cell Mol Physiol, 278:988-99.
54. Peterman A, Cella D, Glandon G, et al. 2001. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr, 29:45-51.
55. Peterson DE, Cariello A. 2004. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Sem Oncol, 31:35-44.
56. Peterson D, Beck S, Keefe D. 2004. Novel therapies. Sem Oncol Nursing, 20:53-8.
57. Pitten FA, Kiefer T, Buth C, et al. 2003. Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomised, controlled study. J Hosp Infect, 53:283-91.
58. Popescu RA, Norman A, Ross PJ, et al. 1999. Adjuvant or palliative chemotherapy for colorectal cancerin patients 70 years or older. J Clin Oncol, 17:2412-8.
59. Pytlik R, Benes P, Patorkova M et al. 2002. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomised, double-blind placebo controlled study. Bone Marrow Transplant, 30:953-61.
60. Rao Naidu MU, Venkat Ramana G, Usha Rani P, et al. 2004. Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia, 6:423-31.
61. Reynolds CM, Levine JE, Uberti JP, et al. 2004. Keratinocyte Growth Factor (Palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host disease (aGvHD) in patients at high risk of a GvHD [abstract]. Blood, 104:1228.
62. Rogers PD, Jenkins JK, Chapman SW, et al. 1998. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis, 178:1726-33.
63. Rubenstein EB, Peterson DE, Schubert M, et al. 2004. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 100:2026-46.
64. Rubin JS, Osada H, Finch PW, et al. 1989. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci USA, 86:802-6.
65. Saadeh CE. 2005. Chemotherapy and radiotherapy-induced oral mucositis: review of perspective strategies and treatment. Pharmacotherapy, 25:540-54.
66. Sharma R, Tobin P, Clarke SJ. 2005. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol, 6:93-102.
67. Skubitz KM, Anderson PM. 1996. Oral glutamine to prevent chemotherapy induced stomatatis: a pilot study. J Lab Clin Med, 127:223-8.
68. Sonis ST, Elting LS, Keefe D, et al. 2004. Perspectives on cancer therapy-induced mucosal injury. Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer, 100:1995-2025.
69. Sonis ST. 2004. A biological approach to mucositis. J Support Oncol, 2:21-36.
70. Sonis ST. 1998. Mucositis as a biologic process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol, 34:39-43.
71. Sonis ST. 2002. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplasic therapy. Crit Rev Oral Biol Med, 13:380-9.
72. Spencer A, Horvath N, Gibson J, et al. 2005. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant, 35:971-7.
73. Spielberger R, Stiff P, Bensinger W, et al. 2004. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med, 351:10-18.
74. Trotti A, Byhardt R, Stetz J, et al. 2000. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys, 47:13-47.
75. Ulrich CM, Yasui Y, Storb R, et al. 2001. Pharmacogenetics of methotrexate toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 98:231-4.
76. Vanclée A, Lutgens LC, Oving EB, et al. 2005. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant, 36:907-15.
77. Wang J, Albertson CM, Zheng H, et al. 2002. Short-term inhibition of ADP-induced platelet aggregation by clopidrogel ameliorates radiation-induced toxicity in rat small intestine. Thromb Haemost, 87:122-8.
78. Wardley AM, Jayson GC, Swindell R, et al. 2000. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and hematopoietic progenitor rescue. Br J Haematol, 110:292-9.
79. Wilkes JD. 1998. Prevention and treatment of oral mucositis following cancer chemotherapy. Sem Oncol, 25:538-51.
80. [WHO] World Health Organization. 1996. Cancer pain relief (2nd ed). Genova, Italy: WHO
81. Wright J, Feld R, Knox J. 2005. Chemotherapy-induced oral mucositis: new approaches to prevention and management. Exp Opin Drug Saf, 4:193-200.
82. Wymenga AN, van der Graaf WT, Spijkervet FK, et al. 1997. A new in vitro assay of quantitation of chemotherapy induced mucositis. Br J Cancer, 8:1062-6.
83. Wymenga AN, van der Graaf WT, Hofstra LS, et al. 1999. Phase I study of transforming growth factor-beta 3 mouthwashes for prevention of chemotherapy induced mucositis. Clin Cancer Res, 5:1363-8.